secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001104659-23-029007
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel Q4 net loss $7.4M, cash $18.3M; fadraciclib Phase 2 on track for 1H 2023
--------------------------------------------------------------------------------

- Net loss Q4 2022 $7.4M, full year $21.2M; cash $18.3M as of Dec 31, 2022.
- R&D expenses $6.7M (Q4) and $20.3M (FY) driven by fadraciclib and plogosertib trials.
- Cash runway estimated into Q4 2023 including $4.7M UK R&D tax credit receivable.
- On track to start oral fadraciclib Phase 2 proof-of-concept in 1H 2023; interim data expected 2H 2023.
- Expect final data from fadraciclib dose escalation and initial data from plogosertib dose escalation in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/0001104659-23-029007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000110465923029007/tm238618d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-029007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer